Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2870610rdf:typepubmed:Citationlld:pubmed
pubmed-article:2870610lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2870610lifeskim:mentionsumls-concept:C0002962lld:lifeskim
pubmed-article:2870610lifeskim:mentionsumls-concept:C0017887lld:lifeskim
pubmed-article:2870610lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2870610lifeskim:mentionsumls-concept:C0015260lld:lifeskim
pubmed-article:2870610lifeskim:mentionsumls-concept:C0001516lld:lifeskim
pubmed-article:2870610lifeskim:mentionsumls-concept:C0017243lld:lifeskim
pubmed-article:2870610lifeskim:mentionsumls-concept:C0599724lld:lifeskim
pubmed-article:2870610lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:2870610pubmed:issue2lld:pubmed
pubmed-article:2870610pubmed:dateCreated1986-5-19lld:pubmed
pubmed-article:2870610pubmed:abstractTextTwenty patients on chronic beta-blockade for angina pectoris were included in a double-blind randomized cross-over placebo-controlled study on a 2% nitroglycerin gel administered transdermally by an adhesive. Topinitro. The dose, 2.5-10 mg/day, was individually titrated and each treatment period was 28 days. The effect was evaluated by exercise tests and diary cards for anginal attacks and nitroglycerin tablets consumed. Results. In the 17 patients who completed the trial, active treatment did not influence systolic and diastolic blood pressure or resting and maximal heart rate. Maximal performance increased insignificantly from 92 +/- 23 to 96 +/- 20 W. The level at which 1 mm of ST depression appeared increased from 62 +/- 26 to 73 +/- 28 W (p less than 0.05). The number of attacks decreased significantly, from 92 +/- 30 to 14 +/- 28/4 weeks. The reduction in the number of sublingual nitroglycerin tablets consumed was insignificant. Conclusion. Nitroglycerin adhesive, in individual dosages, may improve signs and symptoms of ischemia.lld:pubmed
pubmed-article:2870610pubmed:languageenglld:pubmed
pubmed-article:2870610pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2870610pubmed:citationSubsetIMlld:pubmed
pubmed-article:2870610pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2870610pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2870610pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2870610pubmed:statusMEDLINElld:pubmed
pubmed-article:2870610pubmed:issn0001-6101lld:pubmed
pubmed-article:2870610pubmed:authorpubmed-author:LindvallKKlld:pubmed
pubmed-article:2870610pubmed:authorpubmed-author:OlssonGGlld:pubmed
pubmed-article:2870610pubmed:authorpubmed-author:BlokCClld:pubmed
pubmed-article:2870610pubmed:authorpubmed-author:RehnqvistNNlld:pubmed
pubmed-article:2870610pubmed:issnTypePrintlld:pubmed
pubmed-article:2870610pubmed:volume219lld:pubmed
pubmed-article:2870610pubmed:ownerNLMlld:pubmed
pubmed-article:2870610pubmed:authorsCompleteYlld:pubmed
pubmed-article:2870610pubmed:pagination147-52lld:pubmed
pubmed-article:2870610pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2870610pubmed:meshHeadingpubmed-meshheading:2870610-...lld:pubmed
pubmed-article:2870610pubmed:meshHeadingpubmed-meshheading:2870610-...lld:pubmed
pubmed-article:2870610pubmed:meshHeadingpubmed-meshheading:2870610-...lld:pubmed
pubmed-article:2870610pubmed:meshHeadingpubmed-meshheading:2870610-...lld:pubmed
pubmed-article:2870610pubmed:meshHeadingpubmed-meshheading:2870610-...lld:pubmed
pubmed-article:2870610pubmed:meshHeadingpubmed-meshheading:2870610-...lld:pubmed
pubmed-article:2870610pubmed:meshHeadingpubmed-meshheading:2870610-...lld:pubmed
pubmed-article:2870610pubmed:meshHeadingpubmed-meshheading:2870610-...lld:pubmed
pubmed-article:2870610pubmed:meshHeadingpubmed-meshheading:2870610-...lld:pubmed
pubmed-article:2870610pubmed:meshHeadingpubmed-meshheading:2870610-...lld:pubmed
pubmed-article:2870610pubmed:meshHeadingpubmed-meshheading:2870610-...lld:pubmed
pubmed-article:2870610pubmed:meshHeadingpubmed-meshheading:2870610-...lld:pubmed
pubmed-article:2870610pubmed:meshHeadingpubmed-meshheading:2870610-...lld:pubmed
pubmed-article:2870610pubmed:meshHeadingpubmed-meshheading:2870610-...lld:pubmed
pubmed-article:2870610pubmed:year1986lld:pubmed
pubmed-article:2870610pubmed:articleTitleEffects on angina pectoris and exercise tests of a 2% nitroglycerin gel adhesive in patients on chronic beta-blockade. A placebo-controlled study.lld:pubmed
pubmed-article:2870610pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2870610pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2870610pubmed:publicationTypeRandomized Controlled Triallld:pubmed